Safety and Efficacy Study of COV155 for Post-operative Bunionectomy Pain

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Mallinckrodt
ClinicalTrials.gov Identifier:
NCT01743625
First received: December 4, 2012
Last updated: January 13, 2014
Last verified: January 2014
  Purpose

The purpose of this study is to show the effectiveness of COV155 compared to placebo in subjects with acute moderate to severe pain following bunionectomy surgery.


Condition Intervention Phase
Pain, Postoperative
Bunion
Drug: COV155
Drug: placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 3 Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel-Group Evaluation of the Safety and Analgesic Efficacy of COV155 Tablets in Moderate to Severe Post-Operative Bunionectomy Pain Followed by an Open-Label Extension

Further study details as provided by Mallinckrodt:

Primary Outcome Measures:
  • SPID48 (Summed pain intensity difference) [ Time Frame: 48 hours ] [ Designated as safety issue: No ]
    48 hour Summed pain intensity difference


Secondary Outcome Measures:
  • Safety and tolerability of COV155 [ Time Frame: 48 hours ] [ Designated as safety issue: Yes ]
    Safety and tolerability to be evaluated with physical exams, vital signs, pulse oximetry, clinical laboratory tests, electrocardiograms, and adverse events

  • Onset of analgesia of COV155 versus placebo [ Time Frame: 48 hours ] [ Designated as safety issue: No ]
    Onset of confirmed perceptible pain relief, time to meaningful pain relief, and time to peak pain intensity difference

  • Analgesic effects of COV155 versus placebo [ Time Frame: 48 hours ] [ Designated as safety issue: No ]
    Pain intensity scores, pain intensity differences, and summed pain intensity differences; pain relief scores and total pain relief; percent responders; mean dosing interval; use of rescue medication; global assessment of subject satisfaction with study treatment.


Enrollment: 406
Study Start Date: November 2012
Study Completion Date: July 2013
Primary Completion Date: May 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: COV155
COV155, loading dose of 3 tablets followed by 2 tablets every 12 hours for 48 hours.
Drug: COV155
COV155 tablets
Other Name: MNK155
Placebo Comparator: Placebo
Matching tablet to COV155 without containing active ingredients, loading dose of 3 tablets followed by 2 tablets every 12 hours for 48 hours.
Drug: placebo

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  • Voluntarily provide written informed consent
  • General good health
  • 18 to 75 years of age
  • Scheduled for primary unilateral first metatarsal bunionectomy (with no collateral procedures)
  • Body mass index ≤33
  • Female subjects eligible if

    • Not pregnant or lactating; not planning to become pregnant for duration of study;
    • Surgically sterile, or have a monogamous partner who is surgically sterile, or at least 2 years postmenopausal, or practicing acceptable birth control for more than 2 months prior to Screening, during the study and for 1 week following last dose of COV155
  • Male subjects must be sterile (biologically or surgically) or use reliable birth control during the study until at least 1 week after the last dose of COV155
  • Classified as either Physical Status-1 (PS) or PS-2 by the American Society of Anesthetists (ASA) Physical Status Classification System.
  • Willing to complete pain assessments and clinic visits.
  • Additional inclusion criterion for randomization into the Double-Blind Phase: Subjects must experience postoperative pain intensity score ≥5 on a 0 to 10 Numerical Pain Rating Score (NPRS) more than 1 hour, and less than 9 hours after discontinuing the nerve block, and at least 30 minutes after the last ice pack has been removed (if used).

Exclusion Criteria

  • Uncontrolled medical condition, serious intercurrent illness, clinically significant general health condition, or extenuating circumstance that may significantly decrease study compliance or otherwise preclude study participation
  • Clinically significant abnormal ECG at Screening
  • Gastric bypass surgery or gastric band
  • Previous abdominal surgery within the past year or history of abdominal adhesions, known or suspected paralytic ileus
  • History of any medical condition that would alter the absorption, distribution, metabolism or excretion of COV155 including but not limited to severe chronic diarrhea, chronic constipation, severe irritable bowel syndrome, or unexplained weight loss
  • History of severe bronchial asthma, hypercarbia, hypoxia or sleep apnea
  • Certain lab abnormalities
  • Addison's disease, benign prostatic hyperplasia, or kidney disease
  • Donated blood or blood components within 3 months prior to Screening or during study
  • Known allergy/hypersensitivity to any opioid analgesics, anesthetics, acetaminophen, non steroidal anti-inflammatory drugs (NSAIDs)
  • History of intolerance to short term opioid use
  • Unable to discontinue the use of prohibited medications or a history of substance or alcohol abuse within 2 years prior to Screening or a positive quantitative urine drug test at Screening
  • Positive for human immunodeficiency virus, hepatitis B or C
  • Dysphagia and/or cannot swallow study treatment whole
  • History of migraine or frequent headaches within the previous 2 years, seizures, or are currently taking anticonvulsants
  • Previously received COV155 in a clinical study, or undergone a bunionectomy within the last 3 months
  • Received any investigational drugs or devices within 4 weeks prior to Screening or during study
  • Active malignancy or history of malignancy within 2 years prior to Screening, other than completely eradicated cervical squamous cell carcinoma in situ or basal skin cancer
  • Currently taking neuroleptics or stable doses of a benzodiazepine
  • Other criteria as specified in the protocol
  • Additional exclusion criterion for randomization into the Double-Blind Phase: Have surgical complications that could compromise the safety of the subject or confound the results of the study.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01743625

Locations
United States, California
Anaheim Clinical Trials
Anaheim, California, United States, 92801
Lotus Clinical Research, LLC
Pasadena, California, United States, 91105
United States, Maryland
Chesapeake Research Group, LLC
Pasadena, Maryland, United States, 21122
United States, Texas
Endeavor Clinical Trails, PA
San Antonio, Texas, United States, 78229
United States, Utah
Jean Brown Research, Inc.
Salt Lake City, Utah, United States, 84124
Sponsors and Collaborators
Mallinckrodt
  More Information

No publications provided

Responsible Party: Mallinckrodt
ClinicalTrials.gov Identifier: NCT01743625     History of Changes
Other Study ID Numbers: COV15010232
Study First Received: December 4, 2012
Last Updated: January 13, 2014
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Hallux Valgus
Pain, Postoperative
Foot Deformities
Musculoskeletal Diseases
Postoperative Complications
Pathologic Processes
Pain
Signs and Symptoms

ClinicalTrials.gov processed this record on April 23, 2014